Over the past decade, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as highly effective glucose and body-weight-lowering agents for individuals with type 2 diabetes (T2DM), obesity, or both [26,27,28,29,30,31,32,33]. Here, GCG is linked to obesity disorder.